{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:08:42Z","timestamp":1762459722623,"version":"3.41.2"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007675","name":"International Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Zika virus (ZIKV) is an arbovirus which shares antigenic similarity and the mosquito vector with dengue viruses (DENVs). ZIKV is a neurotropic virus capable of causing congenital neurodevelopmental birth defects. As ZIKV antibodies (Abs) can potentially enhance infection by DENVs, a preventive ZIKV vaccine must be designed to eliminate antibody dependent enhancement of infection. We developed a Zika Subunit Vaccine (ZSV) consisting of two proteins, ZS and S, in a genetically pre-determined ratio of 1:4, using the methylotrophic yeast Pichia pastoris. ZS is an in-frame fusion of ZIKV envelope domain III with the Hepatitis B virus (HBV) surface antigen, and S is the un-fused HBV surface antigen. Using specific monoclonal Abs we showed the presence of ZS and S in the co-purified material which were found to co-assemble into virus-like particles (VLPs), based on dynamic light scattering and electron microscopic analyses. These VLPs were immunogenic in BALB\/c mice, eliciting Abs capable of neutralizing ZIKV reporter virus particles. Further, the VLP-induced Abs did not enhance a sub-lethal DENV-2 challenge in AG129 mice. This important safety feature, coupled to the well-documented advantage of P. pastoris expression system, warrants further exploration of ZSV VLP as a possible vaccine candidate.<\/jats:p>","DOI":"10.1093\/femspd\/ftz026","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:16:23Z","timestamp":1556219783000},"source":"Crossref","is-referenced-by-count":20,"title":["<i>Pichia pastoris<\/i>-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation"],"prefix":"10.1093","volume":"77","author":[{"given":"Rajgokul K","family":"Shanmugam","sequence":"first","affiliation":[{"name":"Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi -110067, India"}]},{"given":"Viswanathan","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi -110067, India"}]},{"given":"Rahul","family":"Shukla","sequence":"additional","affiliation":[{"name":"Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi -110067, India"}]},{"given":"Upasana","family":"Arora","sequence":"additional","affiliation":[{"name":"Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi -110067, India"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-2248","authenticated-orcid":false,"given":"Sathyamangalam","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi -110067, India"}]},{"given":"Navin","family":"Khanna","sequence":"additional","affiliation":[{"name":"Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi -110067, India"},{"name":"Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad-Gurgaon Expressway, Faridabad-121001, India"}]}],"member":"286","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"2021052203593333400_bib1","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1007\/s00253-014-5732-5","article-title":"Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production","volume":"98","author":"Ahmad","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"key":"2021052203593333400_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"2021052203593333400_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2017.02.005","article-title":"Prospects for a Zika virus vaccine","volume":"46","author":"Barouch","year":"2017","journal-title":"Immunity"},{"key":"2021052203593333400_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jbiosc.2010.05.001","article-title":"Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris","volume":"110","author":"Batra","year":"2010","journal-title":"J Biosci Bioengg"},{"key":"2021052203593333400_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ArilvaxTM and YF-Vax\u00ae) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2021052203593333400_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"2021052203593333400_bib7","doi-asserted-by":"crossref","first-page":"e0005608","DOI":"10.1371\/journal.pntd.0005608","article-title":"Zika virus-like particle (VLP) based vaccine","volume":"11","author":"Boigard","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2021052203593333400_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.actatropica.2009.10.021","article-title":"Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil","volume":"113","author":"Braga","year":"2010","journal-title":"Acta Trop"},{"key":"2021052203593333400_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4269\/ajtmh.2012.11-0770","article-title":"Review: the history of dengue outbreaks in the Americas","volume":"87","author":"Brathwaite\u00a0Dick","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2021052203593333400_bib10","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"2021052203593333400_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1017\/S0950268812001367","article-title":"Force of infection of dengue serotypes in a population-based study in northeast Brazil","volume":"141","author":"Castanha","year":"2013","journal-title":"Epidemiol Infect"},{"key":"2021052203593333400_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.001","article-title":"The immunopathology of dengue and Zika virus infections","volume":"48","author":"Culshaw","year":"2017","journal-title":"Current Opin Immunol"},{"key":"2021052203593333400_bib13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.chom.2016.04.013","article-title":"Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody","volume":"19","author":"Dai","year":"2016","journal-title":"Cell Host Microbe"},{"key":"2021052203593333400_bib14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nature Immunol"},{"key":"2021052203593333400_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coviro.2017.03.006","article-title":"Vaccination strategies against Zika virus","volume":"23","author":"Fernandez","year":"2017","journal-title":"Current Opin Virol"},{"key":"2021052203593333400_bib16","doi-asserted-by":"crossref","first-page":"e00834","DOI":"10.1128\/JVI.00834-17","article-title":"Development of virus-like-particle vaccine and reporter assay for Zika virus","volume":"91","author":"Garg","year":"2017","journal-title":"J Virol"},{"key":"2021052203593333400_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1099\/jgv.0.000381","article-title":"Zika virus: a previously slow pandemic spreads rapidly through the Americas","volume":"97","author":"Gatherer","year":"2016","journal-title":"J Gen Virol"},{"key":"2021052203593333400_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2859-8-13","article-title":"Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: application to intracellular production of Hepatitis B surface antigen","volume":"8","author":"Gurramkonda","year":"2009","journal-title":"Microb Cell Fact"},{"key":"2021052203593333400_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"key":"2021052203593333400_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ni.3539","article-title":"Immunogenic cross-talk between dengue and Zika viruses","volume":"17","author":"Harrison","year":"2016","journal-title":"Nature Immunol"},{"key":"2021052203593333400_bib22","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1016\/j.vaccine.2007.08.024","article-title":"Field effectiveness of vaccination against tick-borne encephalitis","volume":"25","author":"Heinz","year":"2007","journal-title":"Vaccine"},{"key":"2021052203593333400_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4269\/ajtmh.1982.31.830","article-title":"Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence","volume":"3","author":"Henchal","year":"1982","journal-title":"Am J Trop Med Hyg"},{"key":"2021052203593333400_bib23","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"2021052203593333400_bib24","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiw377","article-title":"Zika virus-induced antibody reposne enhances dengue virus serotype 2 replication in vitro","volume":"214","author":"Kawiecki","year":"2016","journal-title":"J Infect Dis"},{"key":"2021052203593333400_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-3155-11-15","article-title":"Dengue-specific subviral nanoparticles: design, creation and characterization","volume":"11","author":"Khetarpal","year":"2013","journal-title":"J Nanobiotechnol"},{"key":"2021052203593333400_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4269\/ajtmh.16-0503","article-title":"Recombinant dengue virus 4 envelope glycoprotein virus-like particles derived from Pichia pastoris are capable of eliciting homotypic domain III-directed neutralizing antibodies","volume":"96","author":"Khetarpal","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2021052203593333400_bib27","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1128\/JCM.00827-07","article-title":"Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization","volume":"45","author":"Kraus","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2021052203593333400_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature"},{"key":"2021052203593333400_bib29","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1128\/JVI.00252-16","article-title":"Zika virus: new clinical syndromes and its emergence in the Western hemisphere","volume":"90","author":"Lazear","year":"2016","journal-title":"J Virol"},{"key":"2021052203593333400_bib30","doi-asserted-by":"crossref","first-page":"aaf8160","DOI":"10.1126\/science.aaf8160","article-title":"Assessing the global threat from Zika virus","volume":"353","author":"Lessler","year":"2016","journal-title":"Science"},{"key":"2021052203593333400_bib31","doi-asserted-by":"crossref","first-page":"e64595","DOI":"10.1371\/journal.pone.0064595","article-title":"Pichia pastoris-expressed dengue 2 envelope forms virus-Like particles without pre-membrane protein and induces high titer neutralizing antibodies","volume":"8","author":"Mani","year":"2013","journal-title":"PLoS One"},{"key":"2021052203593333400_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.15585\/mmwr.mm6506e1","article-title":"Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses-Brazil, 2015","volume":"65","author":"Martines","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021052203593333400_bib33","doi-asserted-by":"crossref","first-page":"e15272","DOI":"10.7554\/eLife.15272","article-title":"Mapping global environmental suitability for Zika virus","volume":"5","author":"Messina","year":"2016","journal-title":"eLife"},{"key":"2021052203593333400_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0140-6736(15)61273-9","article-title":"Zika virus: following the path of dengue and chikungunya?","volume":"386","author":"Musso","year":"2015","journal-title":"Lancet"},{"key":"2021052203593333400_bib35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nm1240","article-title":"Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus","volume":"11","author":"Oliphant","year":"2005","journal-title":"Nature Med"},{"key":"2021052203593333400_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/CMR.00014-16","article-title":"Emerging role of Zika virus in adverse fetal and neonatal outcomes","volume":"29","author":"Panchaud","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2021052203593333400_bib37","first-page":"7","article-title":"Novel membrane extraction procedure for the purification of hepatitis B surface antigen from Pichia pastoris","volume":"898","author":"Patil","year":"2012","journal-title":"J Chromatog"},{"key":"2021052203593333400_bib38","first-page":"747","article-title":"Flaviviruses","volume-title":"Fields Virology","author":"Pierson","year":"2013","edition":"6th edition"},{"key":"2021052203593333400_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12896-016-0280-y","article-title":"Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies","volume":"16","author":"Poddar","year":"2016","journal-title":"BMC Biotechnol"},{"key":"2021052203593333400_bib40","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S1473-3099(18)30063-X","article-title":"Development of vaccines against Zika virus","volume":"18","author":"Poland","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021052203593333400_bib41","doi-asserted-by":"crossref","first-page":"e0006191","DOI":"10.1371\/journal.pntd.0006191","article-title":"A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice","volume":"12","author":"Ramasamy","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2021052203593333400_bib42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20564","article-title":"Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice","volume":"540","author":"Sapparapu","year":"2016","journal-title":"Nature"},{"key":"2021052203593333400_bib43","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/JCM.00975-17","article-title":"Evaluation of a novel reporter virus neutralization test for serological diagnosis of zika and dengue virus infection","volume":"55","author":"Shan","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2021052203593333400_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ebiom.2017.03.006","article-title":"A rapid Zika diagnostic assay to measure neutralizing antibodies in patients","volume":"17","author":"Shan","year":"2017","journal-title":"EBioMed"},{"key":"2021052203593333400_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection","volume":"353","author":"Stettler","year":"2016","journal-title":"Science"},{"key":"2021052203593333400_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41426-017-0007-8","article-title":"Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses","volume":"7","author":"Tai","year":"2018","journal-title":"Emerg Microb Infect"},{"key":"2021052203593333400_bib47","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1473-3099(17)30534-0","article-title":"Vaccine against Zika virus must remain a priority","volume":"17","author":"The Lancet Infectious Diseases Editorial Board","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021052203593333400_bib48","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fmicb.2015.01005","article-title":"Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies","volume":"6","author":"Tripathi","year":"2015","journal-title":"Front Microbiol"},{"key":"2021052203593333400_bib49","doi-asserted-by":"crossref","first-page":"e01181","DOI":"10.1128\/JVI.01181-17","article-title":"An envelope-modified tetravalent dengue virus-like particle vaccine has implications for flavivirus vaccine design","volume":"91","author":"Urakami","year":"2017","journal-title":"J Virol"},{"key":"2021052203593333400_bib50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.copbio.2013.02.024","article-title":"New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris","volume":"24","author":"Vogl","year":"2013","journal-title":"Current Opin Biotechnol"},{"key":"2021052203593333400_bib51","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1128\/JVI.00216-15","article-title":"Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice","volume":"89","author":"Watanabe","year":"2015","journal-title":"J Virol"},{"key":"2021052203593333400_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12916-018-1067-x","article-title":"Zika vaccines and therapeutics: landscape analysis and challenges ahead","volume":"16","author":"Wilder-Smith","year":"2018","journal-title":"BMC Medicine"},{"volume-title":"WHO Vaccine Pipeline Tracker","year":"2018","author":"World Health Organization","key":"2021052203593333400_bib53"},{"key":"2021052203593333400_bib54","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1016\/j.vaccine.2017.04.052","article-title":"Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus","volume":"35","author":"Yang","year":"2017","journal-title":"Vaccine"},{"key":"2021052203593333400_bib55","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.1038\/s41598-017-08247-9","article-title":"Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"2021052203593333400_bib56","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2016.07.020","article-title":"Structural basis of Zika virus-specific antibody protection","volume":"166","author":"Zhao","year":"2016","journal-title":"Cell"}],"container-title":["Pathogens and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/femspd\/advance-article-pdf\/doi\/10.1093\/femspd\/ftz026\/28533402\/ftz026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/77\/3\/ftz026\/38097532\/ftz026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/77\/3\/ftz026\/38097532\/ftz026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T04:02:20Z","timestamp":1621656140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femspd\/article\/doi\/10.1093\/femspd\/ftz026\/5480462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/femspd\/ftz026","relation":{},"ISSN":["2049-632X"],"issn-type":[{"type":"electronic","value":"2049-632X"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,4,1]]},"article-number":"ftz026"}}